Rigel Pharmaceuticals (RIGL) Goodwill & Intangibles (2022 - 2026)

Rigel Pharmaceuticals has reported Goodwill & Intangibles for 5 years, with the latest figure at $24.2 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 8.87% year-over-year to $24.2 million; the trailing twelve-month figure through Mar 2026 stood at $24.2 million (down 8.87% YoY), and the FY2025 full-year result was $24.7 million, down 8.68% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $24.2 million, down from $24.7 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $28.9 million in Q1 2024, with the low at $13.9 million in Q4 2023.
• Average Goodwill & Intangibles over 5 years is $22.2 million, with a median of $25.0 million recorded in 2025.
• Year-over-year, Goodwill & Intangibles surged 96.6% in 2024 and fell 8.87% in 2026.
• Tracing RIGL's Goodwill & Intangibles over 5 years: stood at $15.0 million in 2022, then decreased by 7.48% to $13.9 million in 2023, then jumped by 95.27% to $27.1 million in 2024, then fell by 8.68% to $24.7 million in 2025, then slipped by 2.38% to $24.2 million in 2026.
• The last three Goodwill & Intangibles figures came in at $24.2 million (Q1 2026), $24.7 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.

Peer Comparison